Insights

Expanding Diagnostic Portfolio Mirxes is actively building a comprehensive cancer detection portfolio including tests for lung, thyroid, colorectal, breast, liver, and ovarian cancers. This diversification presents opportunities to offer complementary diagnostic solutions and advanced testing platforms to support their product development pipeline and commercialization efforts.

Global Market Reach With operations and distribution networks spanning Southeast Asia, the USA, Japan, China, and multiple countries worldwide, Mirxes is positioned to seek partnerships and sales collaborations with international healthcare providers, laboratories, and hospitals to expand the adoption of their diagnostic tests across diverse markets.

Innovation in At-Home Testing The launch of at-home screening kits like FITRapid and HELICORapid in Thailand indicates a strategic move towards democratizing diagnostics and increasing accessibility. Opportunities exist to promote remote testing solutions and digital health integrations to broaden their user base and penetrate new regions.

Strong Financial Backing Mirxes has secured significant funding through multiple IPOs and investments, accumulating hundreds of millions USD, which signifies stability and a focus on growth. This financial strength creates prospects for sales of high-value diagnostic instruments, lab automation solutions, and ongoing reagent supplies to support expanding testing volumes.

Collaborative Research Leadership Originating from A*STAR and leveraging advanced microRNA detection technology, Mirxes collaborates with top academic and industry partners globally. Potential partnerships with biotech, pharmaceutical, or research organizations can open new channels for co-developing innovative diagnostic assays and clinical solutions.

Mirxes Tech Stack

Mirxes uses 8 technology products and services including WordPress, Webpack, Microsoft 365, and more. Explore Mirxes's tech stack below.

  • WordPress
    Content Management System
  • Webpack
    Development
  • Microsoft 365
    Email
  • Punycode
    Font Scripts
  • imagesLoaded
    Javascript Libraries
  • Google Analytics
    Web Analytics
  • WPForms
    Web Platform Extensions
  • WP Job Openings
    Web Platform Extensions

Media & News

Mirxes's Email Address Formats

Mirxes uses at least 1 format(s):
Mirxes Email FormatsExamplePercentage
FirstLast@mirxes.comJohnDoe@mirxes.com
71%
FirstMiddleLast@mirxes.comJohnMichaelDoe@mirxes.com
12%
FirstLas@mirxes.comJohnDoe@mirxes.com
9%
First.Last@mirxes.comJohn.Doe@mirxes.com
8%

Frequently Asked Questions

Where is Mirxes's headquarters located?

Minus sign iconPlus sign icon
Mirxes's main headquarters is located at Singapore, Central Region 618305 Singapore. The company has employees across 2 continents, including AsiaNorth America.

What is Mirxes's stock symbol?

Minus sign iconPlus sign icon
Mirxes is a publicly traded company; the company's stock symbol is 2629.HK.

What is Mirxes's official website and social media links?

Minus sign iconPlus sign icon
Mirxes's official website is mirxes.com and has social profiles on LinkedInCrunchbase.

What is Mirxes's SIC code NAICS code?

Minus sign iconPlus sign icon
Mirxes's SIC code is 8733 - Noncommercial Research Organizations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Mirxes have currently?

Minus sign iconPlus sign icon
As of May 2026, Mirxes has approximately 154 employees across 2 continents, including AsiaNorth America. Key team members include Chief Executive Officer: Y. W.Cto: Z. R.Chief Investment Officer: I. H.. Explore Mirxes's employee directory with LeadIQ.

What industry does Mirxes belong to?

Minus sign iconPlus sign icon
Mirxes operates in the Biotechnology Research industry.

What technology does Mirxes use?

Minus sign iconPlus sign icon
Mirxes's tech stack includes WordPressWebpackMicrosoft 365PunycodeimagesLoadedGoogle AnalyticsWPFormsWP Job Openings.

What is Mirxes's email format?

Minus sign iconPlus sign icon
Mirxes's email format typically follows the pattern of FirstLast@mirxes.com. Find more Mirxes email formats with LeadIQ.

When was Mirxes founded?

Minus sign iconPlus sign icon
Mirxes was founded in 2014.

Mirxes

Biotechnology ResearchCentral Region, Singapore51-200 Employees

Mirxes is a Singapore-headquartered biotechnology company whose mission is to save lives through early, actionable, and personalized diagnoses across the care continuum.

We are Asia-centered, starting with Southeast Asia, and have global ambitions. We have research, development, manufacturing, and clinical diagnostic operations in Singapore, USA, Japan, and China. We have sales and distribution networks worldwide.

Our flagship product is GASTROClear, the world’s first molecular blood test for early detection of gastric cancer, able to detect around 90% of patients with Stage I and II cancers. 

We continue to build a comprehensive cancer portfolio with early detection tests for lung and thyroid cancer (2022), colorectal and breast cancer (2023), liver and ovarian cancer (2024). We are concurrently building a precision oncology portfolio to provide clinical insights for the complete patient journey.

MiRXES was spun off from A*STAR’s Bioprocessing Technology Institute in 2014 to commercialize an industry-leading qPCR-based technology for microRNA detection. Our ID3EAL discovery tool and workflow has been adopted by top academic and industry partners globally and is backed by the world’s first industry standard for microRNA-base diagnostics.

Our versatile platform technology and capabilities have broad applications in the discovery of biomarkers and diagnosis of diseases. We are starting with early cancer detection, but we will also be addressing unmet clinical needs in cardiovascular, metabolic, and infectious diseases.

We responded to COVID-19 by leveraging our capabilities to mass produce and distribute over 5 million units of the Fortitude COVID-19 RT-PCR test. This made-in-Singapore diagnostic test, developed by A*STAR and Tan Tock Seng Hospital, has been deployed in 13 Singapore hospitals and clinical labs and exported to over 45 countries worldwide. Post-COVID, we will leverage this network to commercialize multi-cancer early detection tests.

Section iconCompany Overview

Headquarters
Singapore, Central Region 618305 Singapore
Website
mirxes.com
SIC Code
8733 - Noncommercial Research Organizations
Stock Symbol
2629.HK
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2014
Employees
51-200

Section iconFunding & Financials

  • $250M$500M

    Mirxes's revenue is estimated to be in the range of $250M$500M

Section iconFunding & Financials

  • $250M$500M

    Mirxes's revenue is estimated to be in the range of $250M$500M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.